Modified GRF (1–29)
CJC-1295 no DAC / Mod GRF 1-29 / Modified GRF 1-29
- Peptide length
- 29 amino acids
Modified GHRH fragment without DAC
Open the sources to check how the studies were done and what they can support.
A name used for modified GHRH (1–29) preparations lacking the albumin-binding drug-affinity complex of CJC-1295.
- Family
- GHRH analog
- Research target
- GHRH receptor pathway
- Molecular form
- Modified GHRH fragment without DAC
What to know about the research
The published long-acting CJC-1295 human trial is not evidence for a no-DAC product. Resolve the exact substitutions before matching a source.
Check the exact compound
Require a complete sequence, stereochemistry and terminal form. Market use of “CJC-1295 no DAC” is not a standardized structural specification.
What supports this entry?
1 of 3 summary statements linked to checked source passages.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
Check the evidence limitationSource checked
The published long-acting CJC-1295 human trial is not evidence for a no-DAC product. Resolve the exact substitutions before matching a source.
Briefing cover and page 4, section II.A: separately named DAC and non-DAC substances
Abstract: Objective and Design identify the long-acting molecule studied
- The clinical study is intentionally not attached as a study of this non-DAC record. The 2024 briefing is not a current legal determination.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
The remaining statements still need individual source mapping. Use the original references when checking a claim.
How we prepare and correct these entries